Company intelligence / Profile preview

Inozyme Pharma

Boston, Massachusetts, United Statesinozyme.com ↗

Ownership: Public · INZY
Employees: ~67
Development stage: Phase 2

Overview

Positive interim results in infants and young children with ENPP1 Deficiency showed improvements in survival, heart function, and stabilization or reduction in ectopic calcification and hypophosphatemia. Enrollment is complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency, with topline data expected in early 2026. The company has received regulatory guidance from FDA and EMA for the planned ASPIRE pivotal trial for ABCC6 Deficiency in children.[6]

Therapeutic areas: RheumatologyRare DiseasesNephrology
Modalities: Enzyme Replacement Therapy (ERT)Gene therapy
Industry: Biotech

Drug pipeline

1 asset

AAV-ENPP1-Fc

Preclinical

Partnerships

Yale University

Financials

Market cap: $258.2M
Total revenue: $0
Enterprise value: $220.4M

Beyond the preview

Go deeper on Inozyme Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inozyme Pharma.

Explore the full profile